SNG!!!16 Jun 2020 19:20
UK biotech startup Synairgen is another firm that became a stock market hit in the midst of the crisis. Starting the year at around 6p, its shares rose to above 70p on Aim in April. But like Fusion and Omega, Synairgen has fallen in recent weeks, currently sitting at 36p.
Earlier this week, the company received approval to test its leading candidate, SNG001, for treating patients with coronavirus.